NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.